Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) Equity Average: 2020-2025

Historic Equity Average for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Sep 2025 value amounting to $148.5 million.

  • Arcutis Biotherapeutics' Equity Average fell 13.41% to $148.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $148.5 million, marking a year-over-year decrease of 13.41%. This contributed to the annual value of $123.1 million for FY2024, which is 17.45% down from last year.
  • Latest data reveals that Arcutis Biotherapeutics reported Equity Average of $148.5 million as of Q3 2025, which was up 5.47% from $140.8 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Equity Average registered a high of $432.7 million during Q2 2021, and its lowest value of $63.6 million during Q3 2023.
  • In the last 3 years, Arcutis Biotherapeutics' Equity Average had a median value of $150.1 million in 2025 and averaged $140.6 million.
  • Its Equity Average has fluctuated over the past 5 years, first tumbled by 72.71% in 2023, then spiked by 169.65% in 2024.
  • Quarterly analysis of 5 years shows Arcutis Biotherapeutics' Equity Average stood at $330.3 million in 2021, then dropped by 27.29% to $240.2 million in 2022, then crashed by 71.82% to $67.7 million in 2023, then soared by 132.07% to $157.1 million in 2024, then declined by 13.41% to $148.5 million in 2025.
  • Its Equity Average was $148.5 million in Q3 2025, compared to $140.8 million in Q2 2025 and $150.1 million in Q1 2025.